Renovacor (Renovacor) Net Interest Income : $0.34 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Renovacor Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Renovacor's net interest income for the three months ended in Sep. 2022 was $0.29 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2022 was $0.34 Mil.

Renovacor Net Interest Income Historical Data

The historical data trend for Renovacor's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Net Interest Income Chart

Renovacor Annual Data

Trend

Dec20

Dec21

Net Interest Income

-0.15

Renovacor Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Interest Income	Get a 7-Day Free Trial				-0.15	-	-	0.05	0.29

Renovacor Net Interest Income Calculation

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.34 Mil.

Renovacor Net Interest Income Related Terms

Thank you for viewing the detailed overview of Renovacor's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Net Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 8142, Greenwich, CT, USA, 06836

Website

https://www.renovacor.com

Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Executives

Joseph S Carroll	officer: Chief Accounting Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino	director	C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr.	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll	officer: Chief Financial Officer
Jonas Grossman	director	17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook	director, officer: Chief Executive Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen	officer: Chief Scientific Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran	officer: Chief Medical Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco	officer: Interim CFO